英文全称
Recombinant Human CD137/4-1BB/TNFRSF9 protein ,C- His Tag
纯度(Purity)
>90% as determined by SDS-PAGE
内毒素(Endotoxin level)
Please contact with the lab for this information.
蛋白构建(Construction)
A DNA sequence encoding the human TNFRSF9(Met1~Gln186) was fused with the C-terminal His Tag
Accession #
Q07011
表达宿主(Host)
Mammalian cells
种属(Species)
Homo sapiens (Human)
预测分子量(Predicted Molecular Mass)
20.80kDa
制剂(Formulation)
Supplied as solution form in PBS, pH7.5 or lyophilized from PBS, pH7.5.
运输方式(Shipping)
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
稳定性&储存(Stability &Storage)
Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.
复溶(Reconstitution)
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
背景介绍
4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.
分子别名(Alternative Names)
TNFRSF9,4-1BB,CD137,CDw137,ILA
参考文献(References)
Zhao, Yang, Zhang, Lu, Xiong, Zhang, Zhou, Qi, He, Ding, Hu, De Smet, Lu, Huang (2020) Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia Molecular therapy oncolytics 18() 272-281